Clinical Trials Logo

68Ga-PSMA HBED-PET/CT clinical trials

View clinical trials related to 68Ga-PSMA HBED-PET/CT.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02920229 Active, not recruiting - Prostate Cancer Clinical Trials

68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated

GaPSMA
Start date: November 2015
Phase: N/A
Study type: Interventional

Single-center, prospective, diagnostic trial in radically treated patients with biochemical recurrence of prostate cancer. Patients with radically treated prostate cancer with biochemical relapse and negativity of all traditional morphological and functional imaging (transrectal ultrasound, bone scan, 18F-FMC PET/CT, CT/MRI) or doubtful imaging of 2-deoxy-2-[fluorine-18] (18F)-fluoromethylcholine (FMC) PET/CT will receive a Gallio-68 (68Ga)- Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET)/Computed Tomography (CT) scan.